摘要
目的观察阿德福韦酯治疗慢性乙型肝炎(CHB)近期临床疗效及其对CHB患者血清Th1/Th2型细胞因子的影响。方法采用自身对照、开放单一治疗的研究方法,选择40例明确诊断的CHB患者给予阿德福韦酯治疗,疗程48周,观察治疗前后症状、体征改善情况;检测肝功能(ALT、AST)、HBV-DNA、HBeAg和血清IL-4、IFN-γ的水平,并与同期健康体检者30例对照。结果 40例CHB患者中,显效20例,有效17例,无效3例,总有效率92.5%;CHB组治疗后血清ALT、AST显著低于治疗前(P<0.01),HBV-DNA水平明显下降(P<0.01),HBeAg转阴率37.5%;CHB组治疗前血清IL-4水平明显高于健康对照组(P<0.01),IFN-γ水平明显低于健康对照组(P<0.01);治疗48周后CHB组IL-4水平明显下降(P<0.01),IFN-γ水平明显升高(P<0.01)。结论阿德福韦酯治疗CHB近期临床疗效确切,患者依从性好,能纠正CHB患者Th1/Th2失衡状态,明显改善CHB患者肝功能和病毒学指标。
Objective To observe the recently clinical effect of adefovir dipivoxil on chronic hepatitis B （CHB）and its .influence on serum Th1/Th2 type of cytokines. Methods Using self-reflection,open a single treatment research method,choose 40 patients with CHB who were treated with adefovir dipivoxil. After 48 weeks,improvement of symptoms and signs were observed,and ALT,AST, HBV-B,HBeAg and serum IL-d,IFN-γ level were detected. Serum IL-4,IFN-γ level were compared with the healthy control group. Results 40 patients with CHB,the markedly effective was 20 cases,the effective was 17 cases,the invalid was 3 cases;the total effective rate was 92.5%. After treatment,ALT,AST significantly below before treatment （P〈0.01）,HBV-B levels decreased obviously （P〈 0.01）,HBeAg shade rate 37.5%. Before treatment,serum IL-4 level of CHB group was obviously higher than healthy control group（P〈 0.01）,IFN- γ level obviously lower than healthy control group （P〈0.01）. After 48 weeks, IL-4 levels in CHB group decreased obviously（P〈0.01 ）,IFN-γ level increased significantly（P〈0.01）. Conclusion Adefovir dipivoxil recently clinical effect is obvious,Which can correct CHB patients Th1/Th2 unbalance state and improve liver function and irology index.
出处
《中国现代医生》
2011年第14期28-29,44,共3页
China Modern Doctor
